Pooled analysis of the reports of pomalidomide after failure of lenalidomide and (or) bortezomib for multiple myeloma.

Abstract:

:The use of pomalidomide after lenalidomide and (or) bortezomib failure in patients with multiple myeloma is not clearly clarified in clinical practice. We sought to compile the available clinical reports to better understand the effectiveness of pomalidomide after failure of lenalidomide and (or) bortezomib. We searched published reports including pomalidomide, lenalidomide and (or) bortezomib. Seven reports were identified. Pomalidomide-based regimen was pomalidomide plus low-dose dexamethasone (POM + LoDEX). Six randomized controlled trials enrolling a total of 641 patients that evaluated the treatment effects of pomalidomide after lenalidomide and (or) bortezomib failure in patients with multiple myeloma were included. Pooled results showed that the overall response rate (ORR) was 31% in the POM + LoDEX group. Analysis of heterogeneity showed very little (p = 0.997, I(2)  = 0%), suggesting that response rates of POM + LoDEX therapy were consistent across those included trials. Stable disease was achieved in 40% of 603 patients (heterogeneity: p = 0.980, I(2)  = 0%). In those >65 years, overall response was achieved in 32% of 71 patients (heterogeneity: p = 0.77, I(2)  = 0%). POM + LoDEX showed promising activity in the 95 patients with high-risk cytogenetic abnormalities: ORR was 27% (heterogeneity: p = 0.97, I(2)  = 0%). In the pooled analysis, toxicity consisted primarily of myelosuppression: Grade 3 or 4 neutropenia was seen in 53% (heterogeneity: p = 0.857, I(2)  = 0%). Pomalidomide may produce clinical benefits in patients who had shown refractory on prior lenalidomide and (or) bortezomib therapy. Moreover, elder patients and high-risk cytogenetic abnormalities were not negative predictors for pomalidomide response after lenalidomide and (or) bortezomib failure. Copyright © 2015 John Wiley & Sons, Ltd.

journal_name

Hematol Oncol

journal_title

Hematological oncology

authors

Sheng Z,Liu G

doi

10.1002/hon.2192

subject

Has Abstract

pub_date

2016-06-01 00:00:00

pages

102-7

issue

2

eissn

0278-0232

issn

1099-1069

journal_volume

34

pub_type

杂志文章,评审
  • Salvage chemotherapy for relapsed and resistant lymphoma with a carboplatin containing schedule--EPIC.

    abstract::We have treated 11 patients with relapsed or resistant lymphoma with a combination of Etoposide, Prednisolone, Ifosfamide and Carboplatin (EPIC), obtaining complete responses in two patients and partial responses in four patients for an overall response rate of 54 per cent. The treatment was well tolerated with no tox...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900120304

    authors: Richardson DS,Tighe M,Cull G,Johnson SA,Phillips MJ

    更新日期:1994-05-01 00:00:00

  • A double-blind, randomized, controlled trial on N-acetylcysteine for the prevention of acute kidney injury in patients undergoing allogeneic hematopoietic stem cell transplantation.

    abstract::Acute kidney injury (AKI) is one of the complications of hematopoietic stem cell transplantation and is associated with increased mortality. N-acetylcysteine (NAC) is a thiol compound with antioxidant and vasodilatory properties that has been investigated for the prevention of AKI in several clinical settings. In the ...

    journal_title:Hematological oncology

    pub_type: 杂志文章,随机对照试验

    doi:10.1002/hon.2141

    authors: Ataei S,Hadjibabaie M,Moslehi A,Taghizadeh-Ghehi M,Ashouri A,Amini E,Gholami K,Hayatshahi A,Vaezi M,Ghavamzadeh A

    更新日期:2015-06-01 00:00:00

  • Clinical features associated with transformation of cerebriform T-cell lymphoma to a large cell process.

    abstract::Some patients with cerebriform T-cell lymphoma (CTCL) undergo morphologic transformation to a large cell lymphoma. From a series of 113 patients with CTCL, 22 patients were identified with transformed CTCL. Stages of involvement at diagnosis were: I (seven), II (four), III (four), IV (seven). Nine patients had transfo...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900080406

    authors: Greer JP,Salhany KE,Cousar JB,Fields JP,King LE,Graber SE,Flexner JM,Stein RS,Collins RD

    更新日期:1990-07-01 00:00:00

  • Auer rods in the acute myeloid leukemias: frequency and methods of demonstration.

    abstract::One hundred and twenty-five cases of acute myeloid leukemia (AML) were reviewed for the presence of Auer rods by two peroxidase methods. The percentage of Auer rods recognized by Wright-Giemsa (WG) staining was 20.8% but three times higher by peroxidase staining techniques using either benzidine base as a substrate (P...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900050306

    authors: Jain NC,Cox C,Bennett JM

    更新日期:1987-07-01 00:00:00

  • A phase 1 study to evaluate the feasibility and efficacy of the addition of ropeginterferon alpha-2b to imatinib treatment in patients with chronic phase chronic myeloid leukemia (CML) not achieving a deep molecular response (molecular remission 4.5)-AGMT

    abstract::The goal of current management of patients with chronic phase chronic myeloid leukemia (CML) is to reach treatment-free remission with sustained deep molecular remission (DMR) being the prerequisite therefor. Second-generation tyrosine kinase inhibitors can induce deeper and faster remission than imatinib, but are oft...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2786

    authors: Heibl S,Buxhofer-Ausch V,Schmidt S,Webersinke G,Lion T,Piringer G,Kuehr T,Wolf D,Melchardt T,Greil R,Thaler J

    更新日期:2020-12-01 00:00:00

  • COPP chemotherapy for elderly patients with intermediate and high grade non-Hodgkin's lymphoma.

    abstract::One hundred and forty-one consecutive patients above and 231 below the age of 60 years with previously untreated intermediate or high grade non-Hodgkin's lymphoma were included in this study. Patients above the age of 60 years were treated with the COPP chemotherapy regimen. The younger patients, at or below the age o...

    journal_title:Hematological oncology

    pub_type: 临床试验,杂志文章

    doi:10.1002/hon.2900110106

    authors: Liang R,Todd D,Chan TK,Chiu E,Lie A,Ho F

    更新日期:1993-01-01 00:00:00

  • Whole-body magnetic resonance imaging (WB-MRI) in lymphoma: State of the art.

    abstract::The improvements in magnetic resonance imaging (MRI) technology and the concern related to the increased cancer risk in patients with lymphoma, also due to radiation exposure associated with imaging examinations, have led to the introduction of whole-body MRI (WB-MRI) as a radiation-free alternative to standard imagin...

    journal_title:Hematological oncology

    pub_type: 杂志文章,评审

    doi:10.1002/hon.2676

    authors: Albano D,Bruno A,Patti C,Micci G,Midiri M,Tarella C,Galia M

    更新日期:2020-02-01 00:00:00

  • The sulfone syndrome secondary to dapsone prophylaxis in a patient undergoing unrelated hematopoietic stem cell transplantation.

    abstract::Dapsone is commonly used for pneumocystis carinii pneumonia (PCP) prophylaxis in immunocompromised patients. It has been used as an alternative therapy in the hematopoietic stem cell transplant (HSCT) setting in patients who can't tolerate trimethoprim-sulfamethoxazole. The Sulfone syndrome is not a well-known sequela...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.780

    authors: Abidi MH,Kozlowski JR,Ibrahim RB,Peres E

    更新日期:2006-09-01 00:00:00

  • Cytogenetics and molecular genetics of childhood leukemia.

    abstract::Childhood leukemia is the commonest form of childhood cancer and represents clonal proliferation of transformed hemopoietic cells as a result of genetic changes. Molecular characterization of these changes, in particular chromosomal translocations, has yielded a wealth of information on the mechanisms of leukemogenesi...

    journal_title:Hematological oncology

    pub_type: 杂志文章,评审

    doi:10.1002/(sici)1099-1069(199909)17:3<91::aid-hon643

    authors: Ma SK,Wan TS,Chan LC

    更新日期:1999-09-01 00:00:00

  • Plasma concentration of itraconazole in patients receiving chemotherapy for hematological malignancies: the effect of famotidine on the absorption of itraconazole.

    abstract::Fungal infection is a serious complication in immunocompromised patients, especially those with neutropenia. Itraconazole (ITZ) is expected to be an effective prophylactic agent for fungal infection because it has more activity against Aspergillus species than fluconazole and it is less toxic than amphotericin-B. Howe...

    journal_title:Hematological oncology

    pub_type: 临床试验,杂志文章

    doi:10.1002/(sici)1099-1069(1998030)16:1<33::aid-hon62

    authors: Kanda Y,Kami M,Matsuyama T,Mitani K,Chiba S,Yazaki Y,Hirai H

    更新日期:1998-03-01 00:00:00

  • Aberrant immunoarchitecture distinguishes hyperplastic germinal centres in pattern 1 angioimmunoblastic T-cell lymphoma from reactive follicles.

    abstract::We compare 30 biopsies each of Pattern 1 angioimmunoblastic T-cell lymphoma (AITL1) and reactive lymphoid hyperplasia (RLH) by immunohistology, in-situ hybridization for Epstein-Barr virus-encoded RNA and T-cell receptor-γ (TRG)-clonality. AITL1 cases, more often than RLH controls, were older [median ages 61 (range 23...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2116

    authors: Tan LH,Tan SY

    更新日期:2014-09-01 00:00:00

  • Minimal residual disease (MRD) in non-Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network.

    abstract::In 2009, the four laboratories of the Fondazione Italiana Linfomi (FIL) minimal residual disease (MRD) Network started a collaborative effort to harmonize and standardize their methodologies at the national level, performing quality control (QC) rounds for follicular lymphoma (FL) and mantle cell lymphoma (MCL) MRD as...

    journal_title:Hematological oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1002/hon.2652

    authors: Della Starza I,Cavalli M,De Novi LA,Genuardi E,Mantoan B,Drandi D,Barbero D,Ciabatti E,Grassi S,Gazzola A,Mannu C,Agostinelli C,Piccaluga PP,Bomben R,Degan M,Gattei V,Guarini A,Foà R,Galimberti S,Ladetto M,Ferrero

    更新日期:2019-10-01 00:00:00

  • Hepatitis B-related serological events in hematopoietic stem cell transplant patients and efficacy of lamivudine prophylaxis against reactivation.

    abstract::Reactivation of remote hepatitis B infection (RHBI) is an important cause of morbidity in hematopoietic cell transplant (HCT) patients. We analyzed the prevalence of RHBI in 205 patients who underwent HCT in our centre, serological events related to hepatitis B virus (HBV) reactivation and role of lamivudine prophylax...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2195

    authors: Gupta A,Punatar S,Gawande J,Bagal B,Mathew L,Bhat V,Kannan S,Khattry N

    更新日期:2016-09-01 00:00:00

  • A risk factor for relapse in Hodgkin's disease: female gender?

    abstract::A retrospective study of 163 patients with Hodgkin's disease treated between 1969 and 1987 was performed to identify adverse prognostic factors. One hundred and thirty-five patients (83 per cent) attained a complete remission and 42 (31 per cent) of these have relapsed (median follow-up--43 months). Using multivariate...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900070503

    authors: Jeffery GM,Colls BM,Robinson BA,Fitzharris BM,Atkinson CH

    更新日期:1989-09-01 00:00:00

  • Hematopoietic stem cell transplantation for diffuse large B-cell lymphoma having 8q24/MYC rearrangement in Japan.

    abstract::The prognosis of diffuse large B-cell lymphoma (DLBCL) having MYC rearrangement (MYC-R), including double hit lymphoma (DHL), is poor by standard immunochemotherapy. To evaluate the significance of hematopoietic stem cell transplantation (SCT) for DLBCL with MYC-R, we retrospectively analyzed Japanese SCT registry dat...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2811

    authors: Takahashi T,Suzuki R,Yamamoto G,Nakazawa H,Kurosawa M,Kobayashi T,Okada M,Akasaka T,Kim SW,Fukuda T,Ichinohe T,Atsuta Y,Suzumiya J

    更新日期:2020-09-26 00:00:00

  • In vitro maturation is a viable option for urgent fertility preservation in young women with hematological conditions.

    abstract::Fertility preservation embraces different techniques developed to improve young women chances of becoming mothers after healing. Among them, in vitro maturation (IVM) procedure is based on oocyte retrieval without any gonadotropin treatment, feasible under locoregional or local anesthesia, with very low operative comp...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2724

    authors: Sonigo C,Bajeux J,Boubaya M,Eustache F,Sifer C,Lévy V,Grynberg M,Sermondade N

    更新日期:2020-10-01 00:00:00

  • Establishment of a novel human B-cell line (OZ) with t(14;18)(q32;q21) and aberrant p53 expression was associated with the homozygous deletions of p15INK4B and p16INK4A genes.

    abstract::The novel human pre-B cell line OZ was established from a patient with an aggressive form of non-Hodgkin's lymphoma. Karyotypic analysis of both the primary tumour and OZ cells revealed several marker chromosomes, including the t(14;18)(q32;q21) translocation, which involves the Bcl-2 gene, and alterations on chromoso...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/(sici)1099-1069(199708)15:3<109::aid-hon60

    authors: Nagai M,Fujita M,Ohmori M,Matsubara S,Taniwaki M,Horiike S,Tasaka T,Koeffler HP,Takahara J

    更新日期:1997-08-01 00:00:00

  • Cytokinetic study on the effects of N4-behenoyl-1-beta-D-arabinofuranosylcytosine on murine leukemic cells L 1210: a comparison with the effects of 1-beta-D-arabinofuranosylcytosine.

    abstract::The effects of N4-behenoyl-1-beta-D-arabinofuranosylcytosine (BH-AC) on the cell cycle of murine leukemic cells (L 1210 cells) were compared with those of 1-beta-D-arabinofuranosylcytosine (ara-C), known to be effective for acute leukemia. In a cytokinetic study, a combination of Feulgen microcytofluorometry and triti...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900030106

    authors: Maruo N,Horiuchi H,Nakabo T,Kondo M,Nakamura T

    更新日期:1985-01-01 00:00:00

  • Residual mediastinal widening following therapy in Hodgkin's disease.

    abstract::The chest radiograms (CXR) of 102 patients with Hodgkin's disease presenting with mediastinal involvement at diagnosis were reviewed to assess the incidence and relevance of residual mediastinal abnormalities after therapy. All patients had completed planned treatment and had no evidence of persisting extramediastinum...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900080303

    authors: Orlandi E,Lazzarino M,Brusamolino E,Caldera D,Morra E,Dore R,Di Giulio G,Bernasconi C

    更新日期:1990-05-01 00:00:00

  • Real world outcomes with Bortezomib Thalidomide dexamethasone and Cyclophosphamide Bortezomib dexamethasone induction treatment for transplant eligible multiple myeloma patients in a Latin American country. A Retrospective Cohort Study from Grupo Argentin

    abstract::Data about treatment outcomes and toxicity in Latin America are scarce. There are differences with central countries based on access to healthcare system and socioeconomic status. Argentinean Society of Hematology recommends bortezomib-based triplets for induction treatment of transplant eligible newly diagnosed multi...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2729

    authors: Schütz NP,Ochoa P,Duarte P,Remaggi G,Yantorno S,Corzo A,Zabaljauregui S,Shanley C,Lopresti S,Orlando S,Verri V,Quiroga L,García CA,Fernández V,Fantl D

    更新日期:2020-08-01 00:00:00

  • Rearrangement of human T cell receptor beta and gamma chain genes in adult T cell leukemia/lymphoma.

    abstract::We studied rearrangement of human T cell receptor genes (TCR) of C beta, C gamma, V gamma and J gamma in 34 cases of adult T cell leukemia/lymphoma (ATLL), consisting of 29 cases with monoclonally integrated HTLV-I proviral DNA (ATLL-W) and five without monoclonal integration (ATLL-O), in comparison with 12 cases of o...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900080207

    authors: Ohshima K,Yoshida T,Kikuchi M,Masuda Y,Kimura N,Satoh H

    更新日期:1990-03-01 00:00:00

  • Low-dose radiotherapy in diffuse large B-cell lymphoma.

    abstract::Low-dose radiotherapy (LDRT) given in 2 × 2 Gy is a highly effective and safe treatment for palliation of indolent lymphomas. Otherwise, very little regarding the use of LDRT for diffuse large B-cell lymphoma (DLBCL) has been investigated. We designed a phase 2 trial of LDRT in patients with DLBCL with indication for ...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2368

    authors: Furlan C,Canzonieri V,Spina M,Michieli M,Ermacora A,Maestro R,Piccinin S,Bomben R,Dal Bo M,Trovo M,Gattei V,Tirelli U,Franchin G,Bulian P

    更新日期:2017-12-01 00:00:00

  • Siltuximab in relapsed/refractory multicentric Castleman disease: Experience of the Italian NPP program.

    abstract::Because of the rarity of the disease, randomized clinical trials for multicentric Castleman disease (MCD) remain a challenge and, as a consequence, there is no established standard of care. Siltuximab is a chimeric immunoglobulin G1κ monoclonal antibody against human IL-6 which was recently approved by FDA. Eligible p...

    journal_title:Hematological oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1002/hon.2532

    authors: Tonialini L,Bonfichi M,Ferrero S,Malipiero G,Nozza A,Argnani L,Zinzani PL

    更新日期:2018-10-01 00:00:00

  • The more basic isoform of eEF1A relates to tumour cell phenotype and is modulated by hyper-proliferative/differentiating stimuli in normal lymphocytes and CCRF-CEM T-lymphoblasts.

    abstract::The elongation factor 1A proteins (eEF1A1/A2) are known to play a role in tumours. We previously found that a more basic isoform of eEF1A (MBI-eEF1A) is present in the cytoskeletal/nuclear-enriched extracts of CCRF-CEM T-lymphoblasts but not in those of normal lymphocytes. To obtain deeper knowledge about MBI-eEF1A bi...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2022

    authors: Scaggiante B,Dapas B,Pozzato G,Grassi G

    更新日期:2013-06-01 00:00:00

  • Acute myeloid leukaemia: expression of MYC protein and its association with cytogenetic risk profile and overall survival.

    abstract::Acute myeloid leukaemia (AML) is a clinically aggressive disease with marked genetic heterogeneity. Cytogenetic abnormalities provide the basis for risk stratification into clinically favourable, intermediate, and unfavourable groups. There are additional genetic mutations, which further influence the prognosis of pat...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2279

    authors: Mughal MK,Akhter A,Street L,Pournazari P,Shabani-Rad MT,Mansoor A

    更新日期:2017-09-01 00:00:00

  • Oral idarubicin in the treatment of acute myelogenous leukaemia and the blast phase of chronic myeloid leukaemia.

    abstract::Fourteen patients with poor-risk acute myelogenous leukaemia (AML) and five patients with accelerated phase/blast crisis chronic myeloid leukaemia (CML) were treated with 3 days of oral idarubicin (25 mg/m2/day). No complete remissions or return to chronic phase CML were observed. A fall in the peripheral blast count ...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900070605

    authors: Malik ST,Tucker J,Rohatiner AZ,Brace W,Lister TA

    更新日期:1989-11-01 00:00:00

  • Detection rate of fluorine-18-fluorodeoxyglucose positron emission tomography in patients with marginal zone lymphoma of MALT type: a meta-analysis.

    abstract::The aim of this article is to meta-analyse published data about the detection rate (DR) of fluorine-18-fluorodeoxyglucose ((18) F-FDG) positron emission tomography (PET) and PET/computed tomography (CT) in the evaluation of patients with marginal zone lymphoma of the mucosa-associated lymphoid tissue (MALT). A compreh...

    journal_title:Hematological oncology

    pub_type: 杂志文章,meta分析,评审

    doi:10.1002/hon.2152

    authors: Treglia G,Zucca E,Sadeghi R,Cavalli F,Giovanella L,Ceriani L

    更新日期:2015-09-01 00:00:00

  • R-CHOP-14 in patients with diffuse large B-cell lymphoma younger than 70 years: a multicentre, prospective study.

    abstract::Several studies have shown that adding rituximab to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) or reducing the interval between chemotherapy cycles from 3 weeks to 2 weeks improves survival in patients with diffuse large B-cell lymphoma (DLBCL). These studies prompted our group (GOTEL) to evaluate...

    journal_title:Hematological oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1002/hon.829

    authors: Rueda A,Sabin P,Rifá J,Llanos M,Gómez-Codina J,Lobo F,García R,Herrero J,Provencio M,Jara C,Grupo Oncológico para el Tratamiento y Estudio de los Linfomas (GOTEL).

    更新日期:2008-03-01 00:00:00

  • Clinical significance and prognosis of MYC translocation in diffuse large B-cell lymphoma.

    abstract::Recent studies have suggested that chromosomal aberrations of the MYC gene locus indicate an unfavorable prognosis in diffuse large B-cell lymphoma (DLBCL). However, there have been few reports on MYC translocation in Chinese patients. One hundred and six cases of DLBCLs were analyzed using interphase fluorescent in s...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.991

    authors: Zhang HW,Chen ZW,Li SH,Bai W,Cheng NL,Wang JF

    更新日期:2011-12-01 00:00:00

  • On point in primary CNS lymphoma.

    abstract::Primary CNS lymphoma (PCNSL) is an aggressive brain tumor that represents a significant challenge both to elucidate its biological pathogenesis as well as to develop definitive precision medicines with minimal collateral toxicity. We highlight the key issues in diagnosis and treatment and focus on emerging technologie...

    journal_title:Hematological oncology

    pub_type: 杂志文章,评审

    doi:10.1002/hon.2761

    authors: Tsang M,Cleveland J,Rubenstein JL

    更新日期:2020-12-01 00:00:00